Yeom Ho Yeop, Hong Samin, Kim Sung Soo, Kim Chan Yun, Seong Gong Je
The Siloam Eye Hospital, Seoul, Korea.
Can J Ophthalmol. 2008 Oct;43(5):563-6. doi: 10.3129/i08-092.
In light of concern about the possible relation between the extensive clinical use of prostaglandin analogues and the development of retinal disorders such as cystoid macular edema, this study investigated the influence of topical application of bimatoprost 0.03% on macular thickness and volume in glaucoma patients with phakic eyes.
A total of 40 eyes in 22 patients with primary open-angle glaucoma or normal-tension glaucoma were evaluated in this study. Optical coherence tomography images were taken before initiation of bimatoprost application and after 1, 2, and 3 months of treatment. In addition, best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were measured, and contrast sensitivity tests and fundus examinations were performed. Changes in various parameters, including macular thickness and volume, were analyzed.
BCVA and contrast sensitivity did not change from baseline over the treatment period. IOP declined by 20% to 25% from baseline for 1 month before stabilizing. Macular thickness and volume did not increase significantly during the 3 months.
Topical application of bimatoprost does not induce clinical or structural changes in the macula, at least in glaucoma patients with phakic eyes. Moreover, bimatoprost effectively lowered IOP without causing macular disorders such as cystoid macular edema.
鉴于对前列腺素类似物广泛临床应用与视网膜疾病（如黄斑囊样水肿）发生之间可能存在的关系的关注，本研究调查了0.03%比马前列素局部应用对有晶状体眼青光眼患者黄斑厚度和体积的影响。
本研究共评估了22例原发性开角型青光眼或正常眼压性青光眼患者的40只眼睛。在开始应用比马前列素之前以及治疗1、2和3个月后拍摄光学相干断层扫描图像。此外，测量最佳矫正视力（BCVA）和眼压（IOP），并进行对比敏感度测试和眼底检查。分析包括黄斑厚度和体积在内的各种参数的变化。
在治疗期间，BCVA和对比敏感度与基线相比没有变化。眼压在稳定前1个月从基线下降了20%至25%。在3个月内黄斑厚度和体积没有显著增加。
至少在有晶状体眼青光眼患者中，比马前列素局部应用不会引起黄斑的临床或结构变化。此外，比马前列素有效地降低了眼压，而不会引起黄斑疾病，如黄斑囊样水肿。
